| Study population | Survivors | Non-survivors | |
---|---|---|---|---|
n = 81 | n = 57 | n = 24 | p | |
Age (years) | 69.6 ± 7.7 | 67.8 ± 7.8 | 74.0 ± 5.6 | 0.001 |
Sex (male, n, %) | 54 (66.7) | 39 (68.4) | 16 (66.7) | 0.606 |
ACS at presentation (n, %) | 27 (33.3) | 19 (33.3) | 8 (33.3) | 1.000 |
CV risk profile | ||||
 BMI (kg/m2) | 30.7 ± 5.4 | 31.4 ± 5.5 | 28.9 ± 3.9 | 0.050 |
 Waist circumference (cm) | 107.6 ± 13.2 | 108.2 ± 14.4 | 106.3 ± 9.8 | 0.562 |
 Hypertension (n, %) | 70 (86.4) | 50 (87.7) | 20 (83.3) | 0.599 |
 Hyperlipidemia (n, %) | 58 (71.6) | 42 (73.7) | 16 (66.7) | 0.522 |
 Total cholesterol (mg/dl) | 190.0 ± 43.1 | 190.0 ± 43.1 | 190.0 ± 43.1 | 0.407 |
 LDL-c (mg/dl) | 117.0 ± 35.1 | 115.1 ± 34.4 | 121.7 ± 37.2 | 0.450 |
 HDL-c (mg/dl) | 43.3 ± 10.8 | 41.9 ± 9.5 | 46.7 ± 13.0 | 0.066 |
 Triglycerides (mg/dl) | 173.1 ± 75.8 | 175.9 ± 78.0 | 166.7 ± 71.6 | 0.623 |
 Active smoking (n, %) | 17 (21.0) | 12 (21.1) | 5 (20.8) | 0.982 |
 Pack years (py) | 19.3 ± 21.8 | 19.5 ± 23.0 | 18.7 ± 19.1 | 0.879 |
 Family history of CAD (n, %) | 37 (45.7) | 31 (54.4) | 6 (25.0) | 0.015 |
 Previous CAD (n, %) | 30 (37.0) | 18 (31.6) | 12 (50.0) | 0.117 |
 Previous PCI (n, %) | 24 (29.6) | 14 (24.6) | 10 (41.7) | 0.124 |
 Previous CABG (n, %) | 2 (2.5) | 1 (1.8) | 1 (4.2) | 0.523 |
 hsCRP (mg/dl) | 13.6 ± 22.5 | 12.4 ± 23.1 | 16.6 ± 21.1 | 0.448 |
 GFR (mg/dl/1.73 m2) | 58.8 ± 5.2 | 59.5 ± 3.8 | 57.1 ± 7.3 | 0.136 |
Other comorbidities | ||||
 COPD (n, %) | 11 (13.6) | 7 (12.3) | 4 (16.7) | 0.599 |
Diabetes severity and therapy | ||||
 Diabetes duration (years) | 11.1 ± 10.0 | 10.3 ± 9.9 | 13.1 ± 9.9 | 0.250 |
 Diabetic polyneuropathy (n, %) | 23 (28.4) | 12 (21.1) | 11 (45.8) | 0.024 |
 Diabetic retinopathy (n, %) | 14 (17.3) | 8 (14.0) | 6 (25.0) | 0.233 |
 HbA1c (%) | 7.1 ± 1.0 | 7.0 ± 1.0 | 7.3 ± 1.0 | 0.155 |
 Insulin (n,%) | 34 (42.0) | 18 (31.6) | 16 (66.7) | 0.003 |
 Metformin (n,%) | 52 (64.2) | 40 (71.4) | 12 (50.0) | 0.066 |
 Sulfonylamides (n, %) | 17 (21.0) | 13 (22.8) | 4 (16.7) | 0.535 |
 Incretins (n, %) | 15 (18.5) | 8 (14.0) | 7 (29.2) | 0.109 |
Other relevant medication | ||||
 Aspirin (n, %) | 77 (95.1) | 54 (94.7) | 23 (95.8) | 0.835 |
 Statin (n, %) | 54 (66.6) | 40 (71.4) | 14 (58.4) | 0.137 |
 ACE or ARBi (n, %) | 58 (71.6) | 42 (76.4) | 16 (66.7) | 0.370 |
 Beta-blocker (n, %) | 62 (76.5) | 46 (80.7) | 16 (66.7) | 0.173 |